797 related articles for article (PubMed ID: 17634486)
1. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
3. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
4. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
5. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
6. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH
BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246
[TBL] [Abstract][Full Text] [Related]
7. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
[TBL] [Abstract][Full Text] [Related]
11. An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.
Borden LS; Wright JL; Kim J; Latchamsetty K; Porter CR
BJU Int; 2007 Mar; 99(3):559-63. PubMed ID: 17155976
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
13. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
[TBL] [Abstract][Full Text] [Related]
14. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
15. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
[TBL] [Abstract][Full Text] [Related]
17. Assessing individual risk for prostate cancer.
Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
[TBL] [Abstract][Full Text] [Related]
18. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
19. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
[TBL] [Abstract][Full Text] [Related]
20. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
